Kassar Rawan, Hachem Ray, Jiang Ying, Chaftari Anne-Marie, Raad Issam
From Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Medicine (Baltimore). 2009 Sep;88(5):279-283. doi: 10.1097/MD.0b013e3181b7c64a.
Bacillus species are biofilm-forming organisms that are associated with Bacillus catheter-related bloodstream infections (CRBSIs). The optimal treatment of Bacillus CRBSIs is not known. Therefore, in the current study, we determined the role of long-term central venous catheter (CVC) removal and treatment with vancomycin compared with other agents in Bacillus CRBSIs by retrospectively reviewing the medical records of cancer patients with Bacillus bacteremia who had been treated at our institution from December 1990 to March 2008. True bacteremia was defined as a positive blood culture (>15 colony-forming units/mL) with signs and symptoms of infection (such as fever and chills). Bacillus CRBSI was defined in accordance with the Infectious Diseases Society of America guidelines as probable or definite. There were 94 Bacillus bacteremia episodes, 93 of which (99%) were Bacillus CRBSIs (28% definite and 71% probable). Neutropenia during bacteremia occurred in 29%. Almost all bacteremia patients (99%) had been treated with antibiotics; 63% had received vancomycin. Sepsis with hypotension occurred in 6%, and endocarditis in 1%. Bacillus isolates were susceptible to linezolid (100%), vancomycin (98%), tetracycline (77%), and rifampin (67%). All 4 recurrences occurred in patients in whom the CVC had not been removed (12%), whereas no recurrences occurred in patients whose CVC had been removed (p = 0.028). Patient outcome, in terms of fever and hospitalization duration after the infection, was similar in patients who had received < or =10 days of systemic antibiotics compared with patients who had received >10 days. In conclusion, catheter retention in patients with Bacillus CRBSIs is associated with a significantly higher recurrence rate. If the CVC is retained, treatment with non-vancomycin antibiotics is associated with significantly shorter hospitalization duration after the infection, which may be because glycopeptide antibiotics have poor activity against bacilli embedded in biofilm.
芽孢杆菌属是形成生物膜的微生物,与芽孢杆菌属导管相关血流感染(CRBSIs)有关。目前尚不清楚芽孢杆菌属CRBSIs的最佳治疗方法。因此,在本研究中,我们通过回顾性分析1990年12月至2008年3月在我们机构接受治疗的芽孢杆菌属菌血症癌症患者的病历,确定了长期拔除中心静脉导管(CVC)以及与其他药物相比使用万古霉素治疗芽孢杆菌属CRBSIs的作用。真性菌血症定义为血培养阳性(>15菌落形成单位/mL)且伴有感染的体征和症状(如发热和寒战)。芽孢杆菌属CRBSI根据美国传染病学会指南定义为可能或确诊。共有94例芽孢杆菌属菌血症发作,其中93例(99%)为芽孢杆菌属CRBSIs(28%确诊,71%可能)。菌血症期间中性粒细胞减少症的发生率为29%。几乎所有菌血症患者(99%)都接受了抗生素治疗;63%接受了万古霉素治疗。6%的患者发生伴有低血压的脓毒症,1%的患者发生心内膜炎。芽孢杆菌属分离株对利奈唑胺(100%)、万古霉素(98%)、四环素(77%)和利福平(67%)敏感。所有4例复发均发生在未拔除CVC的患者中(12%),而拔除CVC患者未出现复发(p = 0.028)。在感染后发热和住院时间方面,接受≤10天全身抗生素治疗的患者与接受>10天治疗的患者的预后相似。总之,芽孢杆菌属CRBSIs患者保留导管与显著更高的复发率相关。如果保留CVC,使用非万古霉素抗生素治疗与感染后显著更短的住院时间相关,这可能是因为糖肽类抗生素对嵌入生物膜中的芽孢杆菌活性较差。